Physician profile
Mark A Scheperle
NPI 1265417034
$89,099.02
in general payments reported to CMS, 2019-2025
93 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $5,850 · 2021: $4,386 · 2022: $14K · 2023: $14K · 2024: $17K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $11K · Travel and Lodging: $3,581 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,604 · Entertainment: $16.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,972.75 |
| Food and Beverage | $11,248.55 |
| Travel and Lodging | $3,580.55 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,604.00 |
| Entertainment | $16.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $43,489.51 | 2019-2025 | Biktarvy, Descovy |
| Otsuka America Pharmaceutical, INC. | $17,160.66 | 2020-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Napo Pharmaceuticals INC | $10,081.81 | 2019-2025 | Mytesi |
| Viiv Healthcare Company | $2,793.37 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Abbvie INC. | $1,472.73 | 2019-2025 | Qulipta, Vraylar, Mavyret |
| Merck Sharp & Dohme LLC | $1,287.54 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Novo Nordisk INC | $1,211.44 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $1,097.76 | 2019-2025 | |
| Lilly USA, LLC | $909.19 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $896.09 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Biotech, INC. | $847.72 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $522.71 | 2021-2025 | Egrifta, Trogarzo |
| Emd Serono, INC. | $460.91 | 2019-2025 | Serostim |
| Allergan, INC. | $436.62 | 2019-2020 | |
| Amarin Pharma, INC. | $380.71 | 2019-2022 |
Show all 93 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Scheperle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.